Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Mepolizumab as an effective treatment in a case of hypophysitis in eosinophilic granulomatosis with polyangiitis

[img]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
237kB

Item Type:Article
Title:Mepolizumab as an effective treatment in a case of hypophysitis in eosinophilic granulomatosis with polyangiitis
Creators Name:Chen, J. and Alexander, T. and Walter-Rittel, T. and Ziagaki, A. and Siffrin, V.
Abstract:Granulomatosis or eosinophilic granulomatosis with polyangiitis (GPA/EGPA) can affect multiple organs resulting in heterogeneous symptoms and phenotypes. Pituitary gland dysfunction rarely occurs in GPA (1–3%) and even less in EGPA (two case reports). Here, we report a case of a 51-year-old female patient with a four-year history of EGPA who presented with new polydipsia and polyuria. Laboratory testing and magnetic resonance imaging (MRI) confirmed pituitary gland dysfunction caused by a hypophysitis. Therapeutic adjustment with a switch from dupilumab to mepolizumab resulted in a decrease in clinical symptoms, inflammation in MRI, and normalization of C-reactive protein in serum. This case underlines hypophysitis as a rare organ involvement also in EGPA. Moreover, this case demonstrates the responsiveness of neuroinflammatory manifestations to the recently approved anti-interleukin-5 monoclonal antibody mepolizumab as a new potential treatment option.
Keywords:Anti-IL5 Blockade, Case Report, Eosinophilic Granulomatosis with Polyangiitis, Bituitary Gland Dysfunction
Source:Therapeutic Advances in Neurological Disorders
ISSN:1756-2856
Publisher:Sage Publications
Volume:16
Page Range:17562864231182519
Date:2023
Official Publication:https://doi.org/10.1177/17562864231182519
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library